Search Results

Your search for Matthew S matches 102 pages

Showing 101 - 102

By Matthew Stenger / Wednesday, October 9, 2013 11:23 AM

Etirinotecan Pegol Active in Patients With Previously Treated Metastatic Breast Cancer

Etirinotecan pegol is a topoisomerase-I inhibitor designed to provide prolonged tumor cell exposure to the active metabolite of irinotecan. In a phase II study reported in The Lancet Oncology, Ahmad Awada, MD, of Jules Bordet Institute, Université Libre de Bruxelles, and colleagues examined...

breast cancer

By Matthew Stenger / Tuesday, October 1, 2013 2:29 PM

Long-Term Results of UK START Trials Support Hypofractionated Adjuvant Radiotherapy in Invasive Early Breast Cancer

The 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses were at least as safe and effective as the historical standard regimen of 50 Gy in 25 fractions as adjuvant therapy for early breast...

May

Today In Oncology

Search Results

Your search for Matthew S matches 102 pages

Etirinotecan Pegol Active in Patients With Previously Treated Metastatic Breast Cancer

Long-Term Results of UK START Trials Support Hypofractionated Adjuvant Radiotherapy in Invasive Early Breast Cancer

Durvalumab After Chemoradiotherapy in Unresectable NSCLC Real-World Use and Outcomes

Dato-DXd in Advanced or Metastatic HR-Positive HER2-Negative or Triple-Negative Breast Cancer

United Kingdoms First Cardio-Oncology Service 10-Year Experience

Improving AML Outcomes Testing for MRD Prior to Bone Marrow Transplant

AI Model May Accurately Predict Mental Health Outcomes in Patients With Cancer